-
BRCAness and PARP Inhibition in Mesothelioma: Implications f
2026-05-09
Borchert et al. (2019) systematically profiled homologous recombination repair (HRR) gene expression in malignant pleural mesothelioma (MPM), revealing a subset of tumors with BRCAness phenotypes susceptible to PARP inhibition. Their findings indicate prognostic markers and therapeutic vulnerabilities that can inform future combinatorial strategies in cancer chemotherapy research.
-
Digoxin: Na+/K+ ATPase Pump Inhibitor for Cardiac and Antivi
2026-05-08
Digoxin enables precise modulation of cardiac contractility and offers a validated platform for studying arrhythmia, heart failure, and chikungunya virus inhibition. This guide covers evidence-backed protocols, advanced troubleshooting, and the latest translational insights for maximizing Digoxin’s impact across cardiovascular and antiviral applications.
-
Lisinopril Dihydrate: Precision ACE Inhibitor for Research M
2026-05-08
Lisinopril dihydrate stands out as a highly selective, long-acting ACE inhibitor, enabling reproducible modeling of hypertension, heart failure, and diabetic nephropathy. This article delivers actionable workflows, troubleshooting insights, and translational context for maximizing research impact with APExBIO's premium-grade compound.
-
Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Interac
2026-05-07
This study reveals that naturally occurring angiotensin peptides, including short C- and N-terminal fragments, significantly enhance binding of the SARS-CoV-2 spike protein to its receptor AXL. The findings expand understanding of renin-angiotensin system peptides beyond cardiovascular regulation and implicate them as modulators of viral entry, with critical implications for both hypertension and COVID-19 research.
-
Technical Guidance for I-BET151 (GSK1210151A) in BET Assays
2026-05-07
I-BET151 (GSK1210151A) is a selective BET bromodomain inhibitor for targeted disruption of BRD2, BRD3, and BRD4, supporting robust cell cycle arrest and apoptosis studies in cancer biology. This compound is best suited for in vitro and in vivo research workflows requiring precise modulation of BET proteins, but is not recommended for diagnostic or therapeutic use.
-
Angiotensin 1/2 (5-7): Precision Tool for RAS-Driven Assays
2026-05-06
Explore the unique assay advantages of Angiotensin 1/2 (5-7), a key peptide for renin-angiotensin system research. This article reveals underappreciated technical nuances and translational opportunities, setting it apart from prior reviews.
-
Gemcitabine HCl: Translational Mastery in Pancreatic Cancer
2026-05-06
This thought-leadership article bridges mechanistic insight with strategic workflow guidance for translational researchers leveraging Gemcitabine HCl in advanced pancreatic cancer models. It synthesizes the biological rationale, rigorous in vivo validation, emerging imaging innovations, and workflow optimization strategies, drawing on the latest multianimal MRI protocol evidence. The narrative establishes how APExBIO’s Gemcitabine HCl enables reproducible, high-throughput studies, while delivering a forward-looking perspective on the future of quantitative tumor suppression research.
-
Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding
2026-05-05
Oliveira et al. (2025) demonstrate that naturally occurring angiotensin peptides, through specific sequence truncations and modifications, significantly increase the binding affinity between the SARS-CoV-2 spike protein and the AXL receptor. These findings have important implications for understanding peptide-mediated contributions to COVID-19 pathogenesis and inform future research into peptide-receptor interactions in infectious disease and cardiovascular contexts.
-
Septin4 Promotes HIF-1α Degradation and Aggravates Hypoxic I
2026-05-05
This study reveals that Septin4 exacerbates hypoxia-induced cardiomyocyte injury by promoting HIF-1α ubiquitination and degradation via the VHL pathway. These findings highlight a novel molecular interaction relevant to ischemic heart disease and offer mechanistic insights for future research into hypoxia adaptation and potential intervention strategies.
-
PAD4-IN-2 TFA: Precision Inhibition of NETs for Tumor Resear
2026-05-04
This thought-leadership article explores PAD4-IN-2 TFA (Compound 5i TFA) as a next-generation, highly selective PAD4 inhibitor designed to address persistent challenges in translational oncology. By dissecting its mechanistic role in histone H3 citrullination and NET formation, reviewing preclinical performance, and offering actionable guidance for translational workflows, it positions PAD4-IN-2 TFA at the forefront of tumor-targeted immune modulation. The discussion bridges mechanistic insight with strategic application, referencing the latest peer-reviewed findings and distinguishing this work from standard product summaries by providing a visionary outlook for future research.
-
Digoxin: Na+/K+ ATPase Pump Inhibitor in Cardiac and Viral M
2026-05-04
Digoxin, a gold-standard Na+/K+ ATPase pump inhibitor, enables high-precision modeling of cardiac contractility and robust, cell-type selective inhibition of chikungunya virus infection. Researchers benefit from APExBIO's high-purity Digoxin for reproducible results in both cardiovascular and antiviral experimental workflows.
-
Pharmacokinetics of Corydalis saxicola Alkaloids in MASH Mod
2026-05-03
This study characterizes how metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics and tissue distribution of Corydalis saxicola Bunting total alkaloids in a high-fat, high-cholesterol diet (HFHCD) mouse model. The findings highlight the role of disease-induced changes in drug-metabolizing enzymes and transporters, informing rational dosage strategies for MASLD/MASH therapies.
-
I-BET151 (GSK1210151A): BET Inhibitor Protocols and QC Guida
2026-05-02
I-BET151 (GSK1210151A) is a selective BET bromodomain inhibitor designed for preclinical research in cancer biology, enabling targeted disruption of BRD2/3/4-mediated transcription. It is not intended for diagnostic or therapeutic use, and optimal results depend on careful adherence to solubility and handling recommendations.
-
Angiotensin I (human, mouse, rat): Reliable RAS Research Wor
2026-05-01
This scenario-driven article addresses common laboratory challenges in renin-angiotensin system research, focusing on experimental reliability, protocol optimization, and data interpretation using Angiotensin I (human, mouse, rat) (SKU A1006). Drawing on recent peer-reviewed findings and validated protocols, it demonstrates how this decapeptide offers reproducible, high-quality solutions across cardiovascular and neuroendocrine assays.
-
Tunable Human Intestinal Organoids: Balancing Self-Renewal a
2026-05-01
This study introduces a chemically controlled human intestinal organoid system capable of fine-tuning the balance between stem cell self-renewal and differentiation. The approach advances the scalability and physiological relevance of organoid models, with implications for tissue modeling and high-throughput screening.